NCT05259319View on ClinicalTrials.gov

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

PHASE1RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Metastatic Non Small Cell Lung CancerMetastatic Bladder CancerMetastatic Renal Cell CarcinomaMetastatic Head and Neck Cancer
Interventions
DRUG

Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]

Treatment given every 21 days during 24 months or until progression

DRUG

Tiragolumab

Treatment given every 21 days during 24 months or until progression

RADIATION

Stereotactic body radiation therapy (SBRT)

Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)

Trial Locations (1)

21000

RECRUITING

Centre Georges François Leclerc (CGFL), Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER